HER-2抗独特型单克隆抗体疫苗-肿瘤疫苗的新探索  

The Vaccine of HER-2 antiidiotypic Monoclonal Antibody: a new Discovery of Tumor Vaccines

作　　者：薛洋[1] 张星[2] 施昀[1] 师建国[1] 

机构地区：[1]第四军医大学基础部病理与病理生理学教研室,陕西西安710032 [2]第四军医大学基础部中心实验室,陕西西安710032

出　　处：《现代生物医学进展》2013年第26期5187-5189,5078,共4页Progress in Modern Biomedicine

摘　　要：乳腺癌作为女性最常见的恶性肿瘤之一,发病率正呈逐年上升趋势。全球每13分钟就有一人死于乳腺癌,并随着发病的不断增加,死亡率也在明显上升。乳腺癌已经在女性恶性肿瘤发病率中占第一位,成为威胁女性健康的"头号杀手"。这其中,大部分的乳腺癌类型均为HER-2+。许多的研究证明如果前期对HER-2过度表达的肿瘤应用针对HER-2的免疫疗法可以有效的控制肿瘤的发展。因此,建立体内的免疫应答可以控制过度表达HER-2的乳腺肿瘤病人的病情发展。随着曲妥珠单抗的产生和投入使用,启发人们发现更广阔的空间去构建针对HER-2的免疫应答的疫苗,从而使抗肿瘤的免疫作用更稳定更强大并且不会产生免疫耐受,进而防止肿瘤复发。因为现在针对HER-2产生的免疫耐受已经制约了肿瘤疫苗的发展,因此现在的研究热点是如何打破免疫耐受更好地发挥抗肿瘤的免疫作用。在这篇文章里,我们将着重介绍模拟HER-2的抗独特型单克隆抗体的应用。Breast cancer as one of the most common malignancies of women, incidence is increasing year by year. In the world every 13 minutes with one died of breast cancer, and with the increase of the disease, mortality is also in increased dramatically .Breast cancer is the first malignant tumor in the incidence of women, and become a threat to women＇s health ＂the leading killer＂. Among them, the most breast cancer types are special genetic marker, known as HER-2＋. Many studies prove that HER-2 immune therapy can effectively control the development of HER-2 over-expressed tumors. Thus, the generation of an anti-HER2 immune response should protect patients from HER2-over-exprassing tumor growth. With the use of trastuzumab, inspire people found a broader space for HER-2 to establish the immune response of the vaccines, which can induce a stable and strong immunity and prevent immunological tolerance and tumor recurrence. Now an immunological tolerance against HER-2 antigen exists＇ representing a barrier to effective vaccination against this oncoprotein. Therefore, the current research hotspot is how to break the immune tolerance and improve anti-tumor immune. In this review, we will focus on the applications of antiidiotypic monoclonal antibodies mimicking HER-2.

关 键 词：乳腺癌 抗独特型单克隆抗体 疫苗 

分 类 号：R457.2[医药卫生—治疗学] R730.5[医药卫生—临床医学]